Clinico-pathological characteristics of triple negative and non triple negative high grade breast carcinomas with and without basal marker (CK5/6 and EGFR) expression at a rural tertiary hospital in India

Breast Cancer: Basic and Clinical Research

Volumn 6, Issue 1, 2012, Pages 21-29

  Choccalingam, Chidambharam ^a   Rao, Lakshmi ^a   Rao, Sruti ^a  

^a KASTURBA MEDICAL COLLEGE   (India)

Author keywords

Basal like; Breast cancer; Ck5 6; Egfr; Triple negative; Tumor grade

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR;

ARTICLE; BREAST CARCINOMA; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DISEASE MARKER; FEMALE; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENETIC ASSOCIATION; GENETIC CORRELATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY;

EID: 84856778273     PISSN: None     EISSN: 11782234     Source Type: Journal    
DOI: 10.4137/BCBCR.S8611     Document Type: Article

References (18)

1. Onitilio AA, Engel JM, Greenlee RT, Mukesh BN. Breast Cancer Subtypes Based on ER/PR and HER2 expression: Comparison of Clinicopathologic Features and Survival. Clin Med Res. Jun 2009;7(1-2):4-13.
2. Dolled-Filhart M, Ryden L, Cregger M, et al. Classification of Breast Cancer using Genetic Algorithms and Tissue microarrays. Clin Cancer Res. Nov 2006;12(21):6459-68.
3. Rakha EA, Ellis IO. Triple-negative/basal-like Breast Cancer: Review. Pathology. Jan 2009;41(1):40-7.
4. Pintens S, Neven P, Drijkoningen M, et al. Triple negative Breast Cancer: A Study from the point of view of Basal CK5/6 and HER-1. J Clin Pathol. Jul 2009;62(7):624-8.
5. Lin C, Chien SY, Chen LS, Kuo SJ, Chang TW, Chen DR. Triple negative Breast Carcinoma is a Prognostic Factor in Taiwanese woman. BMC Cancer. Jun 2009;9:192.
6. Tan DS, Marchió C, Jones RL, et al. Triple negative Breast Cancer: Molecular Profiling and Prognostic Impact in Adjuvant Anthracyclinetreated Patients. Breast Cancer Res Treat. Sep 2008;111(1):27-44.
7. Bertucci F, Finetti P, Cervera N, et al. How Basal are Triple negative Breast Cancer. Int J Cancer. Jul 2008;123:236-40.
8. Cheang MCU, Voduc D, Bajdik C, et al. Basal-like Breast Cancer defined by five Biomarkers has Superior Prognostic Value than Triple Negative Phenotype. Clin Cancer Res. Mar 2008;14:1368-76.
9. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The Catalog of Human Cytokeratins: Patterns of Expression in Normal Epithelia, Tumors and Cultured Cells. Cell. Nov 1982;31(1):11-24.
10. Bocker W, Bier B, Freytag G, et al. An Immunohistochemical Study of Breast using Antibodies to Basal and Luminal Keratins, Alpha-smooth Muscle Actin, Vimentin, Collagen IV and Laminin. Part II: Epitheliosis and Ductal Carcinoma In Situ. Virchows Arch A Pathol Anat Histopathol. 1992;421(4):323-30.
11. Reis-Filho JS, Milanezi F, Carvalho S, et al. Metaplastic Breast Carcinomas exhibit EGFR, but not HER2, Gene Amplification and Overexpression: Immunohistochemical and Chromogenic In Situ Hybridization Analysis. Breast Cancer Res. Oct 2005;7:1028-35.
12. Korsching E, Jeffrey SS, Meinerz W, Decker T, Boecker W, Buerger H. Basal Carcinoma of the Breast Revisited: An Old Entity with New Interpretations. J Clin Pathol. Mar 2008;61:553-60.
13. Livasy CA, Karaca G, Nanda R, et al. Phenotypic Evaluation of the Basal-like Subtype of Invasive Breast Carcinoma. Mod Pathol. Feb 2006; 19(2):264-71.
14. Rakha EA, Tan DS, Foulkes WD, et al. Are Triple Negative Tumors and Basal-like Breast Cancer Synonymous? Breast Cancer Res. Nov 2007; 9(6):404, author reply 405.
15. Arnes JB, Bégin LR, Stefansson I, et al. Expression of Epidermal Growth Factor Receptor in relation to BRCA1 status, Basal-like markers and Prognosis in Breast Cancer. J Clin Pathol. Feb 2009;62(2):139-46.
16. Laakso M, Tanner M, Nilsson J, et al. Basoluminal Carcinoma: A New Biologically and Prognostically Distinct entity between Basal and Luminal Breast Cancer. Clin Cancer Res. Jul 2006;12:4185-91.
17. Remmele W, Dietz W, Schmidt F, Schicketanz KH. Relation of Elastosis to Biochemical and Immunohistochemical Steroid Receptor Findings, Ki-67 and Epidermal Growth Factor Receptor (EGFR) Immunostaining in Invasive Ductal Breast Cancer. Virchows Arch A Pathol Anat Histopathol. 1993;422(4):319-26.
18. Banerjee S, Reis-Filho JS, Ashley S, et al. Basal-like Breast Carcinomas: Clinical Outcome and Response to Chemotherapy. J Clin Pathol. Jul 2006; 59(7):729-35.